Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
NCT00419341
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immune Deficiency
Interventions
BIOLOGICAL:
Human Normal Immunoglobulin for Subcutaneous Administration
Sponsor
CSL Behring